Neurofibromatosis Type
📧 Sign up to get email alerts when something new happens for Neurofibromatosis Type.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-06-11Clinical Trial Update: Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials [NA]
This clinical trial update reports that the medication adherence study in people with Neurofibromatosis type 1 across children, adolescents,…
-
CLINICAL_TRIALS trial_result · 2024-05-06Clinical Trial Update: DPCP to Treat Cutaneous Neurofibromas Associated With NF1 [Phase 1]
Phase 1 trial evaluating diphenylcyclopropenone (DPCP) for treating cutaneous neurofibromas in Neurofibromatosis Type 1 has completed.
-
CLINICAL_TRIALS trial_result · 2024-04-11Clinical Trial Update: Treatment of NF1-related Plexiform Neurofibroma With Trametinib [Phase 2]
A Phase 2 clinical trial evaluating trametinib for NF1-related plexiform neurofibroma is active but not currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-04-04Clinical Trial Update: Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours [Phase 1, Phase 2]
Phase 1/2 trial data on intermittent dosing of selumetinib in children with Neurofibromatosis Type 1-related tumours, including plexiform ne…
-
FDA approval · 2024-01-24FDA Approved: KOSELUGO — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approved a supplemental application for KOSELUGO (selumetinib) from AstraZeneca, resulting in updated labeling for the product.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-12-26Clinical Trial Update: SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors [Phase 2]
Phase 2 clinical trial evaluating MEK inhibitor selumetinib plus mTOR inhibitor sirolimus for malignant peripheral nerve sheath tumors (MPNS…
-
CLINICAL_TRIALS trial_result · 2023-12-05Clinical Trial Update: Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma [Phase 2]
Phase 2 trial update for selumetinib in Neurofibromatosis Type 1 with cutaneous neurofibromas; study completed with results posted in late 2…
-
CLINICAL_TRIALS trial_result · 2023-08-30Clinical Trial Update: Medical Treatment of "High-Risk" Neurofibromas [Phase 2]
Phase 2 clinical trial update on medical treatment of high-risk neurofibromas in Neurofibromatosis type 1 has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults [Phase 2]
Phase 2 trial evaluating cabozantinib for plexiform neurofibromas in NF1 patients (children and adults) has completed with results posted in…
-
CLINICAL_TRIALS trial_result · 2022-08-09Clinical Trial Update: NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) [Phase 2]
A Phase 2 clinical trial of NFX-179 topical gel for adults with Neurofibromatosis type 1 and cutaneous neurofibromas has completed with resu…
-
CLINICAL_TRIALS trial_result · 2022-05-11Clinical Trial Update: Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma [EARLY_Phase 1]
An exploratory Phase 1 study evaluated the histone deacetylase inhibitor AR-42 in vestibular schwannoma and meningioma; the trial was termin…
-
CLINICAL_TRIALS trial_result · 2022-03-15Clinical Trial Update: Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 [Phase 2]
A Phase 2 clinical trial assessing N-acetylcysteine for improving learning and motor behavior in children with Neurofibromatosis type 1 has …
-
FDA approval · 2021-12-22FDA Approved: KOSELUGO — Supplemental Application (AstraZeneca Pharmaceuticals LP)
The FDA approved a supplemental application for KOSELUGO (selumetinib) from AstraZeneca Pharmaceuticals LP.
-
CLINICAL_TRIALS trial_result · 2021-12-06Clinical Trial Update: Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain [Phase 3]
Phase 3 trial evaluating Acceptance and Commitment Training for adolescents and young adults with Neurofibromatosis Type 1 and plexiform neu…
-
CLINICAL_TRIALS trial_result · 2021-11-30Clinical Trial Update: Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma [Phase 2]
Phase 2 trial evaluating low-dose or high-dose lenalidomide in children with NF1-associated recurrent pilocytic astrocytoma or optic pathway…
-
CLINICAL_TRIALS trial_result · 2021-10-27Clinical Trial Update: A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1) [NA]
A terminated clinical trial evaluating INFUSE Bone Graft (BMP-2) for tibial pseudarthrosis in patients with Neurofibromatosis Type 1.
-
CLINICAL_TRIALS trial_result · 2021-01-12Clinical Trial Update: Feasibility and Clinically Application of Magnetic Resonance Fingerprinting [NA]
Clinical trial investigating magnetic resonance fingerprinting in Neurofibromatosis type 1 with brain tumors was terminated; results posted …
-
CLINICAL_TRIALS trial_result · 2020-04-14Clinical Trial Update: Effect of Lamotrigine on Cognition in NF1 [Phase 2, Phase 3]
A clinical trial investigating lamotrigine for cognitive enhancement in Neurofibromatosis Type 1 was terminated after Phase 2/3.
-
FDA approval · 2020-04-10FDA Approved: KOSELUGO — Original Application (AstraZeneca Pharmaceuticals LP)
FDA approved KOSELUGO (selumetinib) through an Original Application for pediatric neurofibromatosis type 1 with inoperable plexiform neurofi…
-
CLINICAL_TRIALS trial_result · 2019-01-31Clinical Trial Update: Internet Support Group for Parents of a Child With Neurofibromatosis Type 1
This document indicates the clinical trial evaluating an Internet support group for parents of a child with Neurofibromatosis type 1 has com…
-
CLINICAL_TRIALS trial_result · 2019-01-10Clinical Trial Update: MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 [Phase 2]
Phase 2 trial of MEK inhibitor PD-0325901 in adolescents and adults with Neurofibromatosis Type 1 and growing or symptomatic, inoperable ple…
-
CLINICAL_TRIALS trial_result · 2018-08-08Clinical Trial Update: Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas [Phase 2]
Phase 2 trial evaluating combination chemotherapy for neurofibromatosis type 1 with progressive plexiform neurofibromas has completed with r…
-
CLINICAL_TRIALS research · 2018-07-11Clinical Trial Update: Vision, Attention and Reading in Neurofibromatosis Type 1 (NF1) Children [NA]
This entry reports a clinical study evaluating vision, attention, and reading in children with Neurofibromatosis Type 1, with no phase or st…
-
CLINICAL_TRIALS trial_result · 2018-05-25Clinical Trial Update: Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors [Phase 2]
Phase 2 clinical trial evaluating combination chemotherapy for stage III/IV malignant peripheral nerve sheath tumors in patients with Neurof…
-
CLINICAL_TRIALS trial_result · 2018-05-03Clinical Trial Update: Spinal Abnormalities in Neurofibromatosis Type 1 (NF1)
The document notes that the University of Utah-sponsored clinical trial on spinal abnormalities in Neurofibromatosis Type 1 has completed.